About to explode, page-11

I think the market has completely under estimated what CYP announced in February. The small float of available stock must be getting smaller by the day as instos buy higher and then sell down to get stock. This can only last for so long in a stock with such explosive upside.

Again, for those who have come in late here is a basic re-cap of why CYP could be worth much more than they currently are. Mesoblast cannot produce stem cells as well as Cynata can. Mesoblast have a market cap of over $1B, Cynata have a market cap of around $65m. It is early days but the days ahead surely must be ones which will draw these two figures closer together. Put simply CYP is too cheap at present. That is why the management are not raising fresh capital, even though the shares have performed well. They must know there is a lot more to come.

Just refresh yourselves reading the following statements from CYP in February:

“Extensive trials at Waisman Biomanufacturing in Madison, Wisconsin have now confirmed this state-of-the-art stem cell manufacturing process is capable of producing MSCs for therapeutic application, consistently, efficiently and economically, in a Good Manufacturing Practice (GMP) production environment.”

“a patent-protected process”

“This is a world-first breakthrough that sets Cymerus™ apart”

“critical milestone”

“An equity research report compiled last year by respected biotech analyst Stuart Roberts saliently noted that should Cynata demonstrate an ability to make cells at industrial scale under GMP then it would be in a position to be a “genuine Stem Cell Revolutionary”. “We have just achieved this important goal.”

“We look forward to aggressively pursuing commercial applications for this game changing therapeutic technology.”

“This is a key requirement for pharmaceutical companies as they move to capture the opportunities presented by stem cell medicine.

“The therapeutic use of MSCs is currently being investigated in more than 200 clinical trials around the world in a diverse range of illnesses, including immune disorders, heart disease, stroke, arthritis, fractures, degenerative disc disease, diabetes, lung disorders and eye disease.”

“We cannot overstate how important this process validation is”

http://cynata.com/uploads/default/source/2015/02/89fd7.15.02.19.CynataAchieves.pdf

Cynata executives, who are openly seeking to partner with a large pharmaceutical or biotech major to monetise the Cymerus technology, are talking up a storm, saying they "cannot overstate how important this process validation is" and claiming that "the risk for our shareholders is that we get bought out too cheap".

Cynata’s executive chairman, Stewart Washer, enthuses that stem cell medicine will “change the world,” proving as revolutionary as antibiotics, and that this is "as close to the fountain of youth as you are going to get".

http://www.businessspectator.com.au...cals/australias-next-big-thing-fountain-youth

Have a look at the video presentation describing Cynata's Cymerus:


They have just proved this works so there are no expensive trials which could fail; they have a global market; 1st mover advantage; 200 clinical trials underway by their future potential clients; reasonable cash levels; active management looking for big pharma partners in US; only 66m shares on issue; seemingly unlimited blue sky potential.

This seems to me to be a stock which could explode and get caught up in a strong upward trend which feeds itself and is hard to stop.  DYOR.